Farxiga® (dapagliflozin) – Expanded indication
May 9, 2023 - AstraZeneca announced the FDA approval of Farxiga (dapagliflozin), to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
Download PDF
